Bio-Techne Clocks 17% Organic Revenue Growth In Q2, Announces $400M Share Buyback


Bio-Techne Corporation TECH has posted Q2 FY22 sales of $269.3 million, up 20% Y/Y, beating the consensus of $266.57 million.

  • Organic growth was 17% compared to the prior year, with acquisitions contributing 3% to revenue growth and foreign currency exchange having an immaterial impact.
  • Adjusted EPS increased 16% Y/Y to $1.88, surpassing the consensus of $1.79.
  • The Protein Sciences segment clocked sales of $205.0 million, up 19% (organic growth of 19%).
  • The Protein Sciences segment's operating margin was 45.5% compared to 46.7% a year ago, impacted by strategic investments to support future growth. 
  • The Diagnostics and Genomics segment's sales increased 23% to $64.5 million, +23% Y/Y (organic growth of 7%), with acquisitions contributing 16% to revenue growth. 
  • The segment's operating margin was 16.9% compared to 15.5%, favorably impacted by volume leverage and product mix.
  • Overall adjusted operating income increased 18% (22% reported) to $102.8 million, resulting in an adjusted operating margin of 38.3%.
  • Share Repurchase: Bio-Techne also approved a new share repurchase program of up to $400 million. The new share repurchase program begins February 2, 2022, and replaces the previous program. 
  • Dividend: The Company announced a quarterly dividend of $0.32 per share, payable on February 25, with a record date of February 11.
  • Price Action: TECH shares closed at $376.41 on Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsDividendsHealth CareBuybacksGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!